Altogether, these findings are clinically corroborated by recent reports that treatment with CFTR modulators such as Ivacaftor and Lumacaftor/Ivacaftor reduced the level of fecal inflammatory markers in patients with CF, although there have been limited studies [64,65,66]. Here, CFTR is linked to cystic fibrosis.